These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7402892)

  • 41. Characterization of anti liver kidney microsomal antibody associated with chronic HDV infection by immunoblotting.
    Lenzi M; Fusconi M; Selleri L; Caselli A; Cassani F; Craxí A; Bianchi FB
    Adv Exp Med Biol; 1989; 257():255-6. PubMed ID: 2694820
    [No Abstract]   [Full Text] [Related]  

  • 42. [Acute thrombopenic purpura after ingestion of tienilic acid].
    Hugues FC; Dellas JA; Allamargot M; Marche J
    Nouv Presse Med; 1982 Jun; 11(29):2226-7. PubMed ID: 7202191
    [No Abstract]   [Full Text] [Related]  

  • 43. Adverse reactions associated with ticrynafen use.
    McLain DA; Garriga FJ; Kantor OS
    JAMA; 1980 Feb 22-29; 243(8):763-4. PubMed ID: 7351817
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ticrynafen-induced acute renal failure.
    Powers D; Vaziri ND; Muhalwas K; Hubbell FA; Weber M; Mirahmadi K
    Clin Toxicol; 1981 Apr; 18(4):425-30. PubMed ID: 7237970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The treatment of mild to moderate essential hypertension with tienilic acid (ticrynafen).
    Rosendorff C
    S Afr Med J; 1980 Jun; 57(26):1069-72. PubMed ID: 6996137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Heterogeneity of antimicrosomal autoantibodies in chronic hepatitis C virus infection and delta hepatitis].
    Durazzo M; Costa C; Schmidt E; Loges S; Scaglione L; Touscoz AG; Smedile A; Manns MP; Rizzetto M; Pagano G
    Ann Ital Med Int; 1995; 10(2):93-7. PubMed ID: 7542466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute renal failure during treatment with ticrynafen.
    Sawa H; Yamakawa H; Renjel LE; Fernandes M
    JAMA; 1980 Feb 22-29; 243(8):766-7. PubMed ID: 7351819
    [No Abstract]   [Full Text] [Related]  

  • 48. [For instance Selacryn].
    Bauch W
    Med Welt; 1980 Feb; 31(7):III. PubMed ID: 7366404
    [No Abstract]   [Full Text] [Related]  

  • 49. Counterimmunoelectrophoresis (CIE) for the detection of anti-liver-kidney microsome (LKM) antibodies in the sera of patients with chronic liver disease.
    Lenzi M; Fusconi M; Selleri L; Caselli A; Cassani F; Bianchi FB; Pisi E
    J Immunol Methods; 1988 Jul; 111(2):253-9. PubMed ID: 3397549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multicentre controlled trial of tienilic acid in hyperuricaemic, hypertensive subjects, with intensive monitoring of liver function.
    Br J Clin Pharmacol; 1983 May; 15(5):513-8. PubMed ID: 6344896
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute renal failure from ticrynafen.
    Cohen LH; Norby LH; Champion C; Spargo B
    N Engl J Med; 1979 Nov; 301(21):1180. PubMed ID: 492284
    [No Abstract]   [Full Text] [Related]  

  • 52. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-liver-kidney microsome antibody is a marker for the rat hepatocyte endoplasmic reticulum.
    De Lemos-Chiarandini C; Alvarez F; Bernard O; Homberg JC; Kreibich G
    Hepatology; 1987; 7(3):468-75. PubMed ID: 3552922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renal tubular degeneration after administration of ticrynafen.
    Sanchez MA; Frier S; Hallac R; Faraggiana T; Churg J
    Arch Pathol Lab Med; 1980 Dec; 104(12):656. PubMed ID: 6893663
    [No Abstract]   [Full Text] [Related]  

  • 55. Total ban on tienilic acid.
    Beevers DG; Walker JM
    Lancet; 1980 Jun; 1(8183):1417. PubMed ID: 6104202
    [No Abstract]   [Full Text] [Related]  

  • 56. The immunoelectron-microscopical demonstration of antibodies against endoplasmic reticulum (microsomes) in chronic aggressive hepatitis and liver cirrhosis.
    Storch W; Cossel L; Dargel R
    Immunology; 1977 Jun; 32(6):941-5. PubMed ID: 885590
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A new antigen recognized by anti-liver-kidney-microsome antibody (LKMA).
    Codońer-Franch P; Paradis K; Gueguen M; Bernard O; Costesec AA; Alvarez F
    Clin Exp Immunol; 1989 Mar; 75(3):354-8. PubMed ID: 2702779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and mode of action of tienilic acid.
    Maass AR; Snow IB; Beg M; Stote RM
    Clin Exp Hypertens A; 1982; 4(1-2):139-60. PubMed ID: 7074982
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical significance of liver function and autoantibodies in patients with acute or chronic drug-induced liver injury].
    Liu YM; Yan HP; Han Y; Zhang LJ; Liu Y; Liao HY; Chen YS; Huang YL; Zhao GQ; Ding HG
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):37-40. PubMed ID: 20128967
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes.
    Todros L; Saracco G; Durazzo M; Abate ML; Touscoz G; Scaglione L; Verme G; Rizzetto M
    Hepatology; 1995 Nov; 22(5):1374-8. PubMed ID: 7590650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.